Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

Shenmiao Yang; Neil E. Kay; Min Shi; Gert Ossenkoppele; Roland B. Walter; Robert Peter Gale

doi:10.1038/s41375-021-01419-7

Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

Shenmiao Yang, Neil E. Kay, Min Shi, Gert Ossenkoppele, Roland B. Walter, Robert Peter Gale

Hematology

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	3364-3370
Number of pages	7
Journal	Leukemia
Volume	35
Issue number	12
DOIs	https://doi.org/10.1038/s41375-021-01419-7
State	Published - Dec 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-021-01419-7

Cite this

@article{f54f14eb5f3145aca0f7e84b912fe701,

title = "Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?",

author = "Shenmiao Yang and Kay, {Neil E.} and Min Shi and Gert Ossenkoppele and Walter, {Roland B.} and Gale, {Robert Peter}",

note = "Funding Information: Profs. Christopher Hourigan (US National Institutes of Health), Emli Monserrat (Univ. Barcelona) and Robin Foa (Universita “La Sapienza” di Roma) kindly reviewed the typescript and made helpful suggestions. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. Funding Information: NEK is on the Advisory Board for Abbvie, Astra Zeneca, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for Agios Pharm, Astra Zeneca, BMS –Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, Rigel. He received research funding from Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics and Tolero Pharmaceuticals. RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., CStone Pharmaceuticals, NexIm-mune Inc. and Prolacta Bioscience; advisor to Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.",

year = "2021",

month = dec,

doi = "10.1038/s41375-021-01419-7",

language = "English (US)",

volume = "35",

pages = "3364--3370",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Measurable residual disease testing in chronic lymphocytic leukaemia

T2 - hype, hope neither or both?

AU - Yang, Shenmiao

AU - Kay, Neil E.

AU - Shi, Min

AU - Ossenkoppele, Gert

AU - Walter, Roland B.

AU - Gale, Robert Peter

N1 - Funding Information: Profs. Christopher Hourigan (US National Institutes of Health), Emli Monserrat (Univ. Barcelona) and Robin Foa (Universita “La Sapienza” di Roma) kindly reviewed the typescript and made helpful suggestions. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. Funding Information: NEK is on the Advisory Board for Abbvie, Astra Zeneca, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for Agios Pharm, Astra Zeneca, BMS –Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, Rigel. He received research funding from Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics and Tolero Pharmaceuticals. RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., CStone Pharmaceuticals, NexIm-mune Inc. and Prolacta Bioscience; advisor to Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85115774206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115774206&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01419-7

DO - 10.1038/s41375-021-01419-7

M3 - Editorial

C2 - 34580401

AN - SCOPUS:85115774206

SN - 0887-6924

VL - 35

SP - 3364

EP - 3370

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this